Fourth, given that some predictors display distinct performances according to the tumor tissue type and that some SNVs included in this dataset are preferentially found in specific tumor types (for example, BRCA1 and BRCA2 mutations are more frequently found in breast and ovarian cancers), this dataset could theoretically favor mutation effect prediction algorithms that are breast cancer-specific. This evidence concerns the gene BRCA1 and breast carcinoma.